181 related articles for article (PubMed ID: 32227647)
1. Population pharmacokinetic analysis of esomeprazole in Japanese subjects with various CYP2C19 phenotypes.
Nagase M; Shimada H; Nii M; Ueda S; Higashimori M; Ichikawa K; Zhang L; Zhou L; Chen Y; Zhou D; Dunyak J; Al-Huniti N
J Clin Pharm Ther; 2020 Oct; 45(5):1030-1038. PubMed ID: 32227647
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling to predict exposures in healthy Japanese subjects with different CYP2C19 phenotypes: Esomeprazole case study
.
Higashimori M; Shimada H; Ichikawa K; Zhou D
Int J Clin Pharmacol Ther; 2020 Jan; 58(1):29-36. PubMed ID: 31657713
[TBL] [Abstract][Full Text] [Related]
3. Optimal dose regimens of esomeprazole for gastric acid suppression with minimal influence of the CYP2C19 polymorphism.
Lou HY; Chang CC; Sheu MT; Chen YC; Ho HO
Eur J Clin Pharmacol; 2009 Jan; 65(1):55-64. PubMed ID: 18751689
[TBL] [Abstract][Full Text] [Related]
4. First-line eradication for Helicobacter pylori-positive gastritis by esomeprazole-based triple therapy is influenced by CYP2C19 genotype.
Saito Y; Serizawa H; Kato Y; Nakano M; Nakamura M; Saito H; Suzuki H; Kanai T
World J Gastroenterol; 2015 Dec; 21(48):13548-54. PubMed ID: 26730167
[TBL] [Abstract][Full Text] [Related]
5. Oral esomeprazole in Japanese pediatric patients with gastric acid-related disease: Safety, efficacy, and pharmacokinetics.
Shimizu T; Nakayama Y; Ishii E; Ida S; Satou T; Tokuhara D; Arai K; Nii M; Rydholm H; Yajima T;
Pediatr Int; 2019 Jan; 61(1):87-95. PubMed ID: 30422368
[TBL] [Abstract][Full Text] [Related]
6. A comparison of the acid-inhibitory effects of esomeprazole and rabeprazole in relation to pharmacokinetics and CYP2C19 polymorphism.
Hunfeld NG; Touw DJ; Mathot RA; van Schaik RH; Kuipers EJ
Aliment Pharmacol Ther; 2012 Apr; 35(7):810-8. PubMed ID: 22324425
[TBL] [Abstract][Full Text] [Related]
7. Potent Gastric Acid Inhibition Over 24 Hours by 4-Times Daily Dosing of Esomeprazole 20 mg.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Kagami T; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Digestion; 2015; 91(4):277-85. PubMed ID: 25924819
[TBL] [Abstract][Full Text] [Related]
8. Evaluating a physiologically based pharmacokinetic model for prediction of omeprazole clearance and assessing ethnic sensitivity in CYP2C19 metabolic pathway.
Feng S; Cleary Y; Parrott N; Hu P; Weber C; Wang Y; Yin OQ; Shi J
Eur J Clin Pharmacol; 2015 May; 71(5):617-24. PubMed ID: 25801493
[TBL] [Abstract][Full Text] [Related]
9. Twice-daily dosing of esomeprazole effectively inhibits acid secretion in CYP2C19 rapid metabolisers compared with twice-daily omeprazole, rabeprazole or lansoprazole.
Sahara S; Sugimoto M; Uotani T; Ichikawa H; Yamade M; Iwaizumi M; Yamada T; Osawa S; Sugimoto K; Umemura K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2013 Nov; 38(9):1129-37. PubMed ID: 24099474
[TBL] [Abstract][Full Text] [Related]
10. Effects of proton pump inhibitors, esomeprazole and vonoprazan, on the disposition of proguanil, a CYP2C19 substrate, in healthy volunteers.
Funakoshi R; Tomoda Y; Kudo T; Furihata K; Kusuhara H; Ito K
Br J Clin Pharmacol; 2019 Jul; 85(7):1454-1463. PubMed ID: 30845361
[TBL] [Abstract][Full Text] [Related]
11. Assessing CYP2C19 Ontogeny in Neonates and Infants Using Physiologically Based Pharmacokinetic Models: Impact of Enzyme Maturation Versus Inhibition.
Duan P; Wu F; Moore JN; Fisher J; Crentsil V; Gonzalez D; Zhang L; Burckart GJ; Wang J
CPT Pharmacometrics Syst Pharmacol; 2019 Mar; 8(3):158-166. PubMed ID: 30520273
[TBL] [Abstract][Full Text] [Related]
12. Potent acid inhibition by vonoprazan in comparison with esomeprazole, with reference to CYP2C19 genotype.
Kagami T; Sahara S; Ichikawa H; Uotani T; Yamade M; Sugimoto M; Hamaya Y; Iwaizumi M; Osawa S; Sugimoto K; Miyajima H; Furuta T
Aliment Pharmacol Ther; 2016 May; 43(10):1048-59. PubMed ID: 26991399
[TBL] [Abstract][Full Text] [Related]
13. Early effects of oral administration of esomeprazole and omeprazole on the intragastric pH.
Iida H; Inamori M; Okuno K; Sekino Y; Sakai E; Okubo H; Higurashi T; Endo H; Hosono K; Yoneda M; Koide T; Takahashi H; Goto A; Kubota K; Saito S; Maeda S; Nakajima A; Gotoh E
Hepatogastroenterology; 2015; 62(138):493-6. PubMed ID: 25916088
[TBL] [Abstract][Full Text] [Related]
14. Effect of High-Dose Esomeprazole on CYP1A2, CYP2C19, and CYP3A4 Activities in Humans: Evidence for Substantial and Long-lasting Inhibition of CYP2C19.
Kaartinen TJK; Tornio A; Tapaninen T; Launiainen T; Isoherranen N; Niemi M; Backman JT
Clin Pharmacol Ther; 2020 Dec; 108(6):1254-1264. PubMed ID: 32558923
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial.
Jing S; Zhu Y; Liu W; Yang K; Hu L; Deng D; Lu C; Lin Y
Adv Ther; 2021 Mar; 38(3):1660-1676. PubMed ID: 33575950
[TBL] [Abstract][Full Text] [Related]
16. Changes in CYP2C19 enzyme activity evaluated by the [(13)C]-pantoprazole breath test after co-administration of clopidogrel and proton pump inhibitors following percutaneous coronary intervention and correlation to platelet reactivity.
Harvey A; Modak A; Déry U; Roy M; Rinfret S; Bertrand OF; Larose É; Rodés-Cabau J; Barbeau G; Gleeton O; Nguyen CM; Proulx G; Noël B; Roy L; Paradis JM; De Larochellière R; Déry JP
J Breath Res; 2016 Jan; 10(1):017104. PubMed ID: 26815196
[TBL] [Abstract][Full Text] [Related]
17. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
Klieber M; Oberacher H; Hofstaetter S; Beer B; Neururer M; Amann A; Alber H; Modak A
J Pharmacol Exp Ther; 2015 Sep; 354(3):426-30. PubMed ID: 26159874
[TBL] [Abstract][Full Text] [Related]
18. Variation in pharmacokinetics of omeprazole and its metabolites by gender and CYP2C19 genotype in Pakistani male and female subjects.
Nazir S; Iqbal Z; Ahmad L; Ahmad S
Pak J Pharm Sci; 2016 May; 29(3):887-94. PubMed ID: 27166533
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics of esomeprazole in patients with preterm preeclampsia.
Gebreyesus MS; Decloedt EH; Cluver CA; Hunfeld NGM; Helgadóttir H; Björnsson ES; Wasmann RE; Denti P
Br J Clin Pharmacol; 2022 Oct; 88(10):4639-4645. PubMed ID: 35599445
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetics and tolerability of HCP1004 (a fixed-dose combination of naproxen and esomeprazole strontium) and VIMOVO® (a marketed fixed-dose combination of naproxen and esomeprazole magnesium) in healthy volunteers.
Choi Y; Han H; Shin D; Lim KS; Yu KS
Drug Des Devel Ther; 2015; 9():4127-35. PubMed ID: 26257511
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
